Potential Efficacy of Shiunko for Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody-Induced Skin Fissure: A Single Institutional Case Series

Similar Items

• High Incidence of C797S Mutation in Patients With Long Treatment History of EGFR Tyrosine Kinase Inhibitors Including Osimertinib
  by: Atsushi Osoegawa, MD, PhD, et al.
  Published: (2021-07-01)
• The EGFR C797S Mutation Confers Resistance to a Novel EGFR Inhibitor CLN-081 to EGFR Exon 20 Insertion Mutations
  by: Yosuke Kagawa, MD, et al.
  Published: (2023-03-01)
• Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations
  by: Kiichiro Ninomiya, MD, PhD, et al.
  Published: (2021-01-01)
• Optimizing Sequential Treatment With EGFR Tyrosine Kinase Inhibitor With a Simulation of the T790M Mutation Rate in EGFR–Mutated Lung Cancer
  by: Naoki Haratake, MD, PhD, et al.
  Published: (2020-11-01)
• Successful crizotinib monotherapy in EGFR-mutant lung adenocarcinoma with acquired MET amplification after erlotinib therapy
  by: Katsuhiro Yoshimura, MD, et al.
  Published: (2017-01-01)